Skip to main content
Oncotarget logoLink to Oncotarget
. 2020 Oct 6;11(40):3633–3645. doi: 10.18632/oncotarget.27702

Exosomes secreted under hypoxia enhance stemness in Ewing’s sarcoma through miR-210 delivery

Matthew J Kling 1, Nagendra K Chaturvedi 2,5, Varun Kesherwani 3, Don W Coulter 2,5, Timothy R McGuire 4, J Graham Sharp 1,5, Shantaram S Joshi 1,
PMCID: PMC7546758  PMID: 33088424

Abstract

Intercellular communication between tumor cells within the hypoxic microenvironment promote aggressiveness and poor patient prognoses for reasons that remain unclear. Here we show that hypoxic Ewing’s sarcoma (EWS) cells release exosomes that promote sphere formation, a stem-like phenotype, in EWS cells by enhancing survival. Analysis of the hypoxic exosomal miRNA cargo identified a HIF-1α regulated miRNA, miR-210, as a potential mediator of sphere formation in cells exposed to hypoxic exosomes. Knockdown of HIF-1α in hypoxic EWS cells led to decreased exosomal miR-210 levels and reduced the capacity of hypoxic exosomes to form spheres. Inhibition of miR-210 in hypoxic spheres attenuated sphere formation and overexpression of miR-210 in normoxic spheres significantly enhanced the number of EWS spheres. Our results indicate that hypoxic exosomal miR-210 targets the proapoptotic protein CASP8AP2 in recipient cells. Moreover, the suppression of CASP8AP2 led to a reduction in apoptotic cells and increased sphere formation. Together, the findings in this study suggest that hypoxic exosomes promote stemness in EWS cells by delivering enriched miR-210 that is capable of down-regulating apoptotic pathways, resulting in the survival of cells with increased sphere formation. Future studies will further investigate the effects of EWS derived exosomal miRNAs on target genes and the role these interactions play in driving aggressiveness in hypoxic EWS tumors.

Keywords: exosomes, hypoxia, Ewing’s sarcoma, stemness, miR-210

INTRODUCTION

Ewing’s sarcoma (EWS) is an aggressive and highly malignant bone tumor that develops in children and adolescents [1]. In 85% of patients, EWS is driven by a chromosomal translocation, t [11, 22] (q24; q12), that results in the fusion protein, EWS-FLI1, which has been shown to regulate key pathways involved in EWS tumorigenesis [2, 3]. This pediatric tumor is treatable with a high degree of success if caught early, however, patients diagnosed with metastases or who relapse have a five-year survival rate of less than 25% and therefore, are considered to have the worst prognosis of all of the bone sarcomas [4]. These poor outcomes can be partly attributed to chemoresistant stem-like cancer cells [5]. Hypoxia is an essential feature of the tumor microenvironment (TME) in many solid tumors and it is suggested that enrichment of stem-like cells occurs within the hypoxic niche [6, 7], however, this mechanism remains poorly understood in EWS. Stabilization and activation of the hypoxia inducible factor HIF -1α in hypoxic tumor cells plays a major role in mediating the adaptive response to low oxygen levels [8]. HIF -1α has been demonstrated to regulate tumor formation and stem cell survival in hypoxic cancer cells by inhibiting apoptosis [9]. Emerging evidence indicates intercellular communication between tumor cells in hypoxic and normoxic regions contributes to functional differences associated with hypoxic tumors [1012].

Recently, small extracellular vesicles called exosomes have been described as important mediators of cell-to-cell communication that transduce signals to neighboring cells and cells outside the local TME [11]. This function may provide a mechanism for how hypoxic cells communicate beyond their hypoxic niche and promote aggressive tumors. In the TME, exosomes range in size from 30–150 nm and carry bioactive lipids, protein, mRNAs, miRNAs and gDNA that can be horizontally transferred to cancer cells that drive tumor growth, progression, metastasis, drug resistance, angiogenesis and induction of pre-metastatic niches [13].

The role of exosomes in EWS has not been extensively explored. Initial reports focused on the mRNA profile in exosomes isolated from EWS cell lines and patient plasma where they identified a common transcript signature that could be used as biomarkers for detection of minimal residual disease [14]. Other reports demonstrated that shCD99 EWS-derived exosomes could transfer enriched miR-34a to recipient EWS cells and stimulate neural differentiation [15] while in another study, EWS-derived exosomes carrying EZH2 mRNA could be delivered intact to mesenchymal stem cells [16].

Studies in other cancer models investigating the role of hypoxic exosomes have provided insight into how hypoxic tumors can secrete exosomes that propagate an aggressive phenotype in cells outside the hypoxic niche. Exosomes released from hypoxic prostate cancer cells enhanced sphere formation in normoxic cells [12], but the authors were unable to elucidate a mechanism describing how hypoxic exosomes promote stemness in normoxic cells. More recently, hypoxia was demonstrated to alter miRNA profiles in cancer-derived exosomes. Furthermore, exosomes have been shown to reprogram cancer cells, genetically and metabolically, through the delivery of their miRNA payload [11]. In breast cancer, hypoxic exosomes containing elevated levels of miR-210 increased migration and proliferation in recipient cancer cells [17]. In hypoxic tumors, miR-210 is directly regulated by HIF -1α at its hypoxia response element and is involved in driving metabolic changes, angiogenesis, cell proliferation, migration, invasion, apoptosis and stemness [18].

The role of hypoxia regulated exosomes and miRNA in EWS is currently unknown and highlights a major gap in scientific knowledge. Therefore, we sought to evaluate the role of hypoxic EWS-derived exosomes on the formation of stem-like cells in EWS. We hypothesized that the transfer of hypoxic derived exosomal miR-210 to normoxic cells silences the proapoptotic member caspase-8-associated protein 2 (CASP8AP2), resulting in increased sphere formation and survival.

RESULTS

HypoxicEXO enhance sphere formation in EWS cells

Expression of HIF-1α was measured in A673 and SK-ES-1 EWS cells cultured under 1% O2 for an increasing duration. In both EWS cell lines, HIF -1α expression stabilized at 6 hrs (Figure 1A). To investigate the role of hypoxia on exosome secretion in EWS, A673 and SK-ES-1 cells were cultured in exosome-free media under normoxic (21%O2) and hypoxic (1%O2) conditions for 48 hours. EWS-derived exosomes were isolated by collecting the supernatant and performing multiple centrifugation and ultracentrifugation steps, followed by microfiltration. The exosomes were analyzed using Nanosight tracking analysis (NTA) to measure particle size and concentration. NTA revealed both A673 and SK-ES-1 exosomes with particle sizes within the expected size range of 30-150 nm (Figure 1B). In both cell lines, the total particle concentration of hypoxic EWS-derived exosomes (HypoxicEXO) secreted was lower than normoxic EWS-derived exosomes (NormoxicEXO) following normalization to cell numbers. Proliferation rates in hypoxic EWS cells were decreased ~30% compared to normoxic cells which was consistent with the differences observed in particle concentration between normoxic and hypoxic cells. Total exosomal protein was also similar to total particle concentration and together, our findings suggest that EWS exosome secretion is dependent on proliferation rates which is consistent with the effects of hypoxia on cell proliferation.

Figure 1. HypoxicEXO enhance sphere formation in EWS cells.

Figure 1

(A) Western blot of HIF-1α in A673 and SK-ES- cells cultured under hypoxia (time points: 0, 6, 24, 48 and 72 hrs.). (B) NanoSight tracking analysis (NTA) of normoxic and hypoxic A673 and SK-ES-1 exosomes showing particle size and relative concentration. (C) Transmission electron micrograph (TEM) of normoxic and hypoxic A673 and SK-ES-1 exosomes. (D) Western blot of TSG101 and CD63 exosome markers and negative control calnexin. α-Tubulin was used as the internal loading control. (E) A673 and SK-ES-1 EWS cells were cultured in normoxic conditions with 20 μg/ml of their respective normoxic and hypoxic exosomes in a sphere assay. Quantification of spheres was performed (magnification, ×10) (Mean ± SEM, n = 3, * P ≤ 0.0008, ** P ≤ 0.003).

EWS NormoxicEXO and HypoxicEXO were visualized using transmission electron microscopy. TEM confirmed small vesicles ranging from 30–150 nm (Figure 1C). We confirmed the presence of EWS-derived exosomes by immunoblotting for protein markers involved in exosome biogenesis. Western blotting demonstrated decreased levels of CD63 and TSG101 in SK-ES-1 HypoxicEXO compared to NormoxicEXO. The endoplasmic reticulum protein calnexin served as a negative control and was not observed in either exosome lysates (Figure 1D). Total protein isolated from NormoxicEXO and HypoxicEXO lysates was reflected in similar levels of α-tubulin. We concluded that our isolation method reliably captures vesicles consistent with exosome characteristics. We next investigated whether hypoxic exosomes promoted stemness in EWS cells outside of a hypoxic environment, we co-cultured EWS NormoxicEXO and HypoxicEXO with normoxic cells in a sphere-forming assay. EWS cells cultured under normal oxygen tension levels demonstrated enhanced sphere formation after adding HypoxicEXO (Figure 1E). SK-ES-1 HypoxicEXO enhanced sphere formation 3.7-fold while A673 HypoxicEXO increased sphere formation by 2.2-fold compared to the effect of their respective NormoxicEXO on normoxic cells. These results suggest that HypoxicEXO could enhance stemness in normoxic EWS cells.

EWS HypoxicEXO carry specific hypoxia regulated miRNA

Recently, hypoxia was demonstrated to alter miRNA profiles in cancer-derived exosomes. Furthermore, exosomes have been shown to genetically and metabolically reprogram cancer cells through the delivery of their miRNA payload [11]. We sought to identify miRNA in our HypoxicEXO that may play a role in promoting stemness. First, total RNA was isolated from normoxic and hypoxic SK-ES-1 cells and their derived exosomes. Capillary electrophoresis revealed a broad composition of RNA with enrichment of small RNAs in the exosomes compared to their respective cells (Figure 2A). Cellular RNA profiles demonstrated typical ribosomal subunit peaks (28S and 18S), but were not seen in the exosomal lysates [19]. The presence of these ribosomal RNAs have been reported in both microvesicles and apoptotic bodies which further supports the high quality of the exosome isolation.

Figure 2. EWS HypoxicEXO carry specific hypoxia regulated miRNA.

Figure 2

(A) Representative electropherogram profile of total RNA in normoxic and hypoxic SK-ES-1 cells and exosomes. Ribosomal subunits 28S and 18S were observed in cellular RNA profiles and were absent in exosomal RNA. Unsupervised cluster analysis of SK-ES-1 miRNAs in (B) normoxic and hypoxic cells and (C) NormoxicEXO and HypoxicEXO. Each column represents a biological replicate and every row denotes an individual miRNA. The Z-score color scale indicates high expression represented by red ranging to low expression denoted by green. Volcano plot of miRNA differentially expressed (≥ 1.5 fold threshold) in SK-ES-1 (D) normoxic compared to hypoxic cells and (E) HypoxicEXO compared to NormoxicEXO. Significance (-log10 p-value) was plotted versus fold change (log2 fold change) along the y and x axis, respectively. (F) Validation of hypoxia regulated miRNAs miR-210 A673 and SK-ES-1 NormoxicEXO and HypoxicEXO using qRT-PCR (Mean ± SEM, n = 3, * P ≤ 0.05). miR-16 was used as a control to normalize miRNA expression.

RNAseq was performed using the Illumina HiSeq3000 to identify exosomal miRNAs. Unsupervised hierarchical clustering identified miRNA clusters that were significantly different between normoxic and hypoxic cells, and NormoxicEXO and HypoxicEXO (Figure 2B, 2C). We observed 467 miRNAs to be differentially expressed between normoxic and hypoxic cells with a threshold for comparison of 1.5 fold with a significance of P < 0.05) (Figure 2D). Hypoxic cells displayed 94 increased and 373 decreased miRNAs compared to normoxic cells. In HypoxicEXO, we observed 75 enriched and 90 depleted miRNAs compared to NormoxicEXO (Figure 2E). Using real-time PCR, we validated the top regulated miRNA observed in both the cellular and exosomal miRNA-seq results and found miR-210 expression to be consistently elevated in HypoxicEXO compared to NormoxicEXO for both EWS cell lines (Figure 2F). These data suggest that hypoxic exosomal miR-210 may influence sphere formation in target cells and could potentially serve as a reliable prognostic marker for hypoxic EWS tumors.

HIF-1α upregulates exosomal miR-210 and mediates HypoxicEXO-induced sphere formation

Since HIF-1α has been shown to regulate the expression of miR-210 in hypoxic cells, we evaluated whether miR-210 levels in hypoxic EWS cells and their HypoxicEXO were HIF-1α dependent by knocking down HIF-1α using siRNAs (siHIF-1α) (Figure 3A). In our HIF-1α knockdown cells, we observed a significant decrease in HIF-1α under hypoxic conditions. Knockdown of HIF-1α significantly decreased miR-210 in both our hypoxic cells (Figure 3B) and in their HypoxicEXO (Figure 3C). In addition, miR-210 levels in the HIF-1α knockdown cells and exosomes were similar to their normoxic controls. These results indicate that miR-210 expression in hypoxic EWS cells and HypoxicEXO is regulated by HIF-1α. Next, we assessed the effect of HypoxicEXO derived from siHIF-1α cells on sphere formation (Figure 3D). Here, HypoxicEXO derived from siHIF-1α cells failed to increase sphere formation compared to control HypoxicEXO. Together, these findings suggest that the stabilization of HIF-1α in hypoxic cells plays a significant role in the HypoxicEXO mediated effects on sphere formation.

Figure 3. HIF-1α upregulates exosomal miR-210 and mediates HypoxicEXO-induced sphere formation.

Figure 3

(A) Western blot of HIF-1α in hypoxic A673 and SK-ES- cells transfected with Non-Targeting control (NTC) and HIF-1α-siRNA. α-Tubulin was used as the internal loading control. (B) Analysis of miR-210 expression levels in A673 and SK-ES-1 cells transfected with NTC and HIF-1α-siRNA, and (C) their respective exosomes using qRT-PCR (Mean ± SEM, n = 3, * P ≤ 0.02, ** P ≤ 0.05, *** P ≤ 0.0002). RNU6B and miR-16 was used as a control to normalize miRNA expression in cells and exosomes, respectively. (D) Assessment of sphere formation in A673 and SK-ES-1 EWS cells cultured in normoxic conditions with 20 μg/ml normoxic and hypoxic exosomes derived from their respective cells transfected with NTC and HIF-1α-siRNA. Quantification of spheres was performed (Mean ± SEM, n = 3, * P ≤ 0.0004, ** P ≤ 0.0001).

miR-210 in HypoxicEXO increases EWS sphere formation

To determine if hypoxic exosomal delivery of miR-210 increases sphere formation, we first needed to measure the effects of hypoxia on sphere formation in EWS cells. EWS cells cultured under hypoxic conditions formed significantly more and larger spheres than cells cultured under normoxia (Figure 4A). Hypoxic spheres expressed significantly elevated levels of miR-210 compared to normoxic spheres (Figure 4B). To study if miR-210 is required for sphere formation in EWS cells, we knocked down miR-210 using inhibitors and overexpressed miR-210 using mimics (Figure 4C and 4D). Inhibition of miR-210 in hypoxic spheres resulted in a significant decrease in sphere formation in both EWS cell lines, however, while the number of spheres formed in hypoxic SK-ES-1 knockdown cells was similar to normoxic spheres, hypoxic A673 knockdown cells had an elevated sphere formation compared to their normoxic spheres. The overexpression of miR-210 in normoxic EWS cells promoted a 9-fold and 2-fold increase in spheres formed in A673 and SK-ES-1 cells, respectively. Normoxic spheres transfected with miR-210 inhibitors or combined mimics with inhibitors demonstrated no significant change in sphere formation in either EWS cell line.

Figure 4. miR-210 in HypoxicEXO increase EWS sphere formation.

Figure 4

(A) Sphere assay of A673 and SK-ES-1 cells grown under normoxic and hypoxic conditions. Quantification of spheres was performed (magnification, ×4) (mean + SEM, n = 3, * P ≤ 0.02, ** P < 0.008). (B) Analysis of miR-210 expression levels in normoxic and hypoxic A673 and SK-ES-1 spheres using qRT-PCR (Mean + SEM, n = 3, * P ≤ 0.5). RNU6B was used as a control to normalize miRNA expression. (C) Sphere assay quantifying A673 and SK-ES-1 cells transfected with either miR-scramble or miR-210 inhibitors under normoxic and hypoxic conditions. (Mean + SEM, n = 3, * P ≤ 0.0001, ** P ≤ 0.005). (D) Sphere assay quantifying A673 and SK-ES-1 cells transfected with miR-scramble, miR-210 mimics, miR-210 inhibitors or 20 μg/ml hypoxic exosomes. (Mean + SEM, n = 3, * P ≤ 0.002, ** P ≤ 0.0001).

To evaluate the role of miR-210 in HypoxicEXO mediated sphere formation, we treated normoxic EWS cells with HypoxicEXO alone and in the presence of cells transfected with miR-210 inhibitors (Figure 4D). The effects of HypoxicEXO on sphere formation were significantly impaired in both A673 and SK-ES-1 cells treated with the miR-210 inhibitor. Together, these results indicated that miR-210 in hypoxic spheres and HypoxicEXO plays a causal role in increasing stemness in EWS cells.

miR-210 silences the proapoptosis member CASP8AP2

To identify a functional mechanism underlying the effects of miR-210 on sphere formation, we analyzed a known miR-210 target gene, the proapoptotic member CASP8AP2. Previous studies utilized miRNA target prediction tools (miRANDA, Sanger MirBase and Targetscan) to identify a miR-210 conserved seed sequence in the CASP8AP2 3′-UTR region [20, 21]. The miR-210 putative target sites in CASP8AP2 were validated using luciferase activity assays and functional studies revealed a prosurvival effect resulting from miR-210 directly silencing CASP8AP2 [2023]. In our hypoxic EWS spheres, expression of CASP8AP2 was significantly decreased compared to normoxic spheres and inhibition of miR-210 in hypoxic spheres restored CASP8AP2 expression when compared to normoxic spheres (Figure 5A). Overexpression of miR-210 decreased CASP8AP2 in normoxic spheres when compared to normoxic controls (Figure 5B). As expected, CASP8AP2 expression was rescued in normoxic spheres cotransfected with miR-210 mimics and inhibitors. Importantly, normoxic spheres treated with HypoxicEXO decreased CASP8AP2 levels, while miR-210 reversed the exosome mediated downregulation of CASP8AP2 (Figure 5B). To demonstrate a direct effect of CASP8AP2 expression on sphere formation, we knocked down CASP8AP2 using siRNAs (Figure 5C). CASP8AP2 knockdown led to significant increases in sphere formation in normoxic cells but had little effect on hypoxic spheres when compared to hypoxic controls (Figure 5D). To further investigate the functional role of CASP8AP2 in the survival of EWS spheres, we assessed apoptosis using Annexin V/PI staining and flow cytometry (Figure 5E). Inhibition of CASP8AP2 in normoxic spheres significantly reduced apoptosis compared to normoxic controls in both cell lines. Interestingly, SK-ES-1 hypoxic control and CASP8AP2 knockdown spheres had similar reductions in apoptosis as the normoxic CASP8AP2 knockdowns, whereas, A673 hypoxic controls demonstrated a further decrease in apoptosis compared to normoxic CASP8AP2 knockdowns. Moreover, CASP8AP2 knockdown further decreased apoptosis in hypoxic spheres compared to the hypoxic control group. Our findings suggest that HypoxicEXO mediated delivery of miR-210 to normoxic EWS spheres mediates the silencing of CASP8AP2 and promotes survival and stemness in EWS cells.

Figure 5. miR-210 silences the proapoptosis member CASP8AP2.

Figure 5

Western blot of CASP8AP2 in (A) A673 and SK-ES-1 Spheres transfected with either miR-scramble or miR-210 inhibitors under normoxic and hypoxic conditions. (B) A673 and SK-ES-1 spheres transfected with miR-scramble, miR-210 mimics, miR-210 inhibitors or 20 μg/ml hypoxic exosomes. (C) A673 and SK-ES-1 spheres transfected with Non-Targeting control (NTC) or CASP8AP2-siRNA. α-Tubulin was used as the internal loading control. (D) Sphere assay quantifying A673 and SK-ES-1 cells transfected with either NTC or CASP8AP2-siRNA under normoxic and hypoxic conditions. (Mean + SEM, n = 3, * P ≤ 0.002, ** P ≤ 0.0002, *** P ≤ 0.0001). (E) Assessment of apoptosis by Annexin V-FITC/PI staining. (Left) Representative plots and (Right) Quantification of Annexin V-FITC stainined A673 and SK-ES-1 spheres transfected with NTC or CASP8AP2-siRNA under normoxic and hypoxic conditions. (Mean + SEM, n = 3, * P ≤ 0.0008, ** P ≤ 0.0001).

DISCUSSION

The hypoxic TME is considered a crucial driver in tumor development and therapy resistance. Aggressive tumors often consist of hypoxic regions capable of creating an environment that supports stem-like cancer cells [6, 7]. In EWS, hypoxia and enrichment of stem-like cells is associated with poor patient outcomes [5, 24]. Mounting evidence suggests that the hypoxic niche may be able to exert its effects beyond the local microenvironment by signaling to nearby normoxic tumor cells [11]. Exosomes have been described as critical mediators of cell-cell communication within the TME and may provide an explanation for how hypoxia contributes to tumors with an aggressive phenotype. Our findings indicate that exosomes secreted under hypoxic conditions significantly increase sphere formation in normoxic EWS cells. Moreover, we show that HIF-1α regulates the HypoxicEXO mediated effect on sphere formation by enriching miR-210 within hypoxic derived exosomes. We demonstrate that the delivery of miR-210 to recipient cells enhances sphere formation by silencing a potential target, the proapoptotic member CASP8AP2, that is critical to the survival of stem-like cells.

Regions within tumors experiencing prolonged hypoxia result in necrosis and are linked to poor patient survival. A clinical study in EWS reported primary tumors with necrotic regions correlated with the worst overall survival in patients who had increased chances of metastases [24]. Recently, a growing body of evidence has shown that exosomes function as a bridge between neighboring cancer cells by delivering an RNA rich cargo [11, 25, 26]. In hypoxic tumors, exosomes have been suggested to contribute to the aggressive phenotype by mediating the cross-talk between tumor cells in hypoxic regions and target cells in normoxic regions [11, 12]. However, the association between hypoxia and exosomes in EWS has yet to be explored. Initial studies demonstrated that HypoxicEXO were being secreted at an elevated rate compared to normoxic cells and was suggested to underly the effects observed in cells exposed to HypoxicEXO [27]. Our findings and others indicate that exocytosis of exosomes is dependent on cellular proliferation, explaining our results demonstrating a decrease in HypoxicEXO secretion [12]. Consistent with this report, our observed HypoxicEXO mediated effects on stemness are most likely due to the exosomal cargo, not hypersecretion. These discrepancies in exosomal secretion could be attributed to the use of exosome isolation methods that poorly discriminate exosomes from microvesicles or apoptotic bodies, however, no isolation approach can totally eliminate these extracellular vesicles. Furthermore, RNA analysis in our exosomes lacked ribosomal peaks which are commonly observed in microvesicles and apoptotic bodies [19].

In cancer patients, exosomes are reportedly elevated within the systemic vasculature compared to normal healthy control patients and carry biomarkers with the potential to detect and monitor the development of tumors [13]. Characterization of mRNA in EWS cells and their derived exosomes was previously performed in order to identify an RNA profile that could be used to detect minimal residual disease following therapy [14]. In our approach, we assessed the miRNA expression profiles in hypoxic and normoxic EWS cells and their derived exosomes. Importantly, the differential expression of our exosomal miRNA cargo revealed selective sorting of small RNAs in HypoxicEXO that in part, reflected the miRNA profile in our hypoxic cells. Detection of hypoxia regulated miRNAs in circulating exosomes have played a major role as prognostic and predictive markers that correlate with metastasis and chemoresistance [27, 28]. We validated the top miRNA, miR-210, that was differentially expressed in our hypoxic cells and HypoxicEXO. These observations are consistent with findings in exosomes derived from hypoxic breast cancer cells and patient samples [27, 29]. Moreover, breast cancer patients with elevated exosomal miR-210 were associated with tumor metastasis [30]. In EWS patients, EWS-FLI1 is the sole diagnostic marker that distinguishes EWS from other sarcomas and bone cancers [3]. In our study, we are the first to show a miRNA profile in EWS exosomes that could serve as biomarkers and assist in the prediction of outcomes in EWS patients with aggressive hypoxic tumors. Future work validating and matching the molecular profiles between exosomes and their parental EWS tumors is needed in order to identify EWS patients with hypoxic tumors and to devise new approaches that can overcome therapy resistant tumors.

In addition to exosomal cargo serving as biomarkers, increasing efforts are being made in elucidating the mechanism’s underlying exosomal miRNAs silencing of target mRNAs in recipient cells, prompting our investigation into the miRNA profile in EWS exosomes. Recent studies in breast cancer revealed exosomal miRNA promoted tumorigenesis in a Dicer-dependent manner and moreover, Dicer was demonstrated to facilitate miRNA processing from pre-miRNA to mature miRNA in exosomes resulting in stable miRNA capable of exerting long lasting pro-tumorigenic effects in recipient cells [31]. Several studies have identified mechanisms describing the effects of HypoxicEXO miRNA cargo in angiogenesis, metastasis, proliferation, migration and invasion, but it is currently unknown how HypoxicEXO delivery of miRNA influences stemness in recipient cells. A previous study indicated exosomes derived from hypoxic prostate cancer cells can enhance sphere formation in normoxic cells [12], however, the underlying molecular mechanism remains unclear. Since HIF-1α is a primary regulator of the hypoxic response, an early study reported enrichment of miR-21 in exosomes derived from hypoxic oral squamous cell carcinoma cells was directly regulated by stable HIF-1α [11]. In our study, we demonstrate that the effects of HypoxicEXO on sphere formation in normoxic EWS cells is regulated by HIF-1α remodeling of the HypoxicEXO miRNA cargo and directly enriching for miR-210. This is supported by our observations showing HypoxicEXO derived from HIF-1α knockdown cells failed to increase sphere formation compared to normoxic control spheres and spheres co-cultured with NormoxicEXO. Given that miR-210 was highly expressed in both our hypoxic cells and exosomes, we are the first to show that increased miR-210 levels in HypoxicEXO are dependent on HIF-1α stabilization. Together, this evidence compelled us to investigate the role of cellular and exosomal miR-210 in promoting stemness in EWS cells.

It is well established that a myriad of miRNAs are capable of targeting overlapping mRNA in cells, especially in recipient cells that have internalized cancer derived exosomes [13, 31, 32]. Our observed effects of HypoxicEXO miRNA content on normoxic spheres might not be the result of a single miRNA, however, our findings indicate that miR-210, is at least one miRNA capable of mediating sphere formation in hypoxic spheres and in spheres co-cultured with HypoxicEXO. Previously, knockdown of miR-210 in hypoxic glioma stem cells was demonstrated to decrease sphere formation and the overall stem cell phenotype [33]. In osteosarcoma stem cells, miR-210 overexpression and knockdown studies revealed that miR-210 can promote stemness and even reprogram differentiated osteosarcoma cells into Stro-1+/CD117+ stem cells [34]. Our study also demonstrated that inhibition of miR-210 could reduce sphere formation in hypoxic spheres. Moreover, when we overexpressed miR-210 in normoxic EWS spheres, it resulted in increased sphere formation consistent with previous studies demonstrating a miR-210 mediated effect on cellular reprogramming [34]. Importantly, we are the first to show in EWS that hypoxia increases sphere formation and in part, sphere formation is regulated by miR-210 expression. In breast cancer, hypoxic derived exosomal miR-210 promoted angiogenesis and proliferation in xenograft tumors [17]. Delivery of HypoxicEXO to normoxic cells in our study indicated that exosomal miR-210 can promote sphere formation. Furthermore, we show that miR-210 can enhance stemness by downregulating CASP8AP2.

This is the first study to describe a mechanism where the miRNA cargo in HypoxicEXO silence a gene involved in regulating the survival of stem-like cells. In hypoxic bone marrow derived mesenchymal stem cells (BM-MSC), miR-210 targeted and silenced CASP8AP2, resulting in an antiapoptotic affect that bolstered the survival of the BM-MSCs [20]. CASP8AP2 is a proapoptotic member that participates in fas-induced and tumor necrosis factor-α- mediated apoptosis signaling [35]. Since EWS cells are thought to derive from transformed BM-MSCs, we chose to investigate if EWS cells can adopt this prosurvival pathway to preserve its stem-like population. Consistent with previous findings, knockdown of miR-210 in our hypoxic spheres resulted in increased CASPA8AP2 expression, while overexpression of miR-210 in normoxic spheres inhibited CASP8AP2 levels [2023, 36]. HypoxicEXO delivering miR-210 demonstrated a similar decrease in CASP8AP2 expression in normoxic spheres. miR-210 exerts pleiotropic antiapoptotic effects on hypoxic cells [20, 33, 37, 38], however, this is the only study in EWS demonstrating a mechanism where miR-210 promotes survival in hypoxic spheres by downregulating an apoptotic pathway. Further studies are needed to elucidate the prosurvival role of miR-210 on stemness and the effects of directly targeting CASP8AP2 and other proapoptotic proteins in hypoxic EWS spheres. Our data suggest that sphere formation is negatively regulated by CASP8AP2 activity. This is supported in our CASP8AP2 knockdown spheres demonstrating significant increases in sphere formation in the normoxic group and slight increases in the hypoxic group. Furthermore, knockdown of CASP8AP2 significantly decreased apoptosis in normoxic spheres. In our hypoxic spheres, CASP8AP2 correlated with a significant decrease in apoptosis, suggesting that hypoxia induces prosurvival mechanisms that are crucial for sphere formation. Future work will investigate the role of CASP8AP2 and other proapoptotic members involved in regulating survival in hypoxic spheres. Supportive of our findings, previous EWS studies showed that resistance to apoptosis in hypoxic cells was dependent on HIF-1α [39, 40]. Together, these studies indicate that CASP8AP2 silencing by miR-210 prevents apoptosis, promoting sphere formation in hypoxic EWS cells and in normoxic cells pretreated with HypoxicEXO.

This study describes a mechanism whereby EWS cells under hypoxic conditions release exosomes that enhance stemness in EWS cells. We identified a hypoxia regulated miRNA significantly expressed in hypoxic cells and HypoxicEXO and characterized a potential target that facilitates an apoptotic pathway critical to sphere formation. Ongoing studies are investigating the role of HIF-1α on regulating EWS stemness and together, our future aim is to investigate how HIF-1α selectively modulates the packaging of miRNAs into HypoxicEXO, and validate additional miRNAs that promote aggressive hypoxic phenotypes.

MATERIALS AND METHODS

Cell culture and hypoxia exposure

EWS cell lines A673 and SK-ES-1 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen, CA, USA) as adherent monolayers in a humidity-controlled incubator at 5% CO2 and 21% O2 at 37°C. Hypoxia experiments for adherent cell growth and sphere formation were performed with a Thermo Scientific™ Heracell™ VIOS CO2 trigas incubator (Thermo Fisher Scientific, Waltham, MA, USA) at 5% CO2/95% N2 and oxygen levels maintained at 1% O2 at 37°C. For exosome isolation, A673 and SK-ES-1 cells were cultured in RPMI-1640 media containing 10% exosome-free FBS (System Biosciences, Palo Alto, CA, USA), 1% glutamine and 5% penicillin/streptomycin (Gibco, Carlsbad, CA, USA). In all studies, cell lines were maintained in culture for no more than 10 passages.

siRNA and miRNA transfection

Pre-designed HIF-1α, CASP8AP2 and Non-Targeting Control (NTC) ON-TARGET plus siRNAs in SMARTpool format were obatained from Dharmacon (Horizon Discovery, Waterbeach, UK). miR-210-3p mimics, miR-210-3p inhibitor and negative control (miR-scramble) mimics were purchased from Ambion (Thermo Fisher Scientific, Waltham, MA, USA). All transient transfections were performed with Lipofectamine RNAiMAX (Invitrogen, Waltham, MA, USA) according to the manufacturer’s instructions Following transfections, cells were used in downstream exosome isolations, sarcosphere assays and/or immunoblotting.

Exosome isolation

Exosomes were prepared from the cell culture supernatant of A673 and SK-ES-1 EWS cells using ultracentrifugation and filtration protocols as described previously [41]. Briefly, EWS cells cultured to 70% confluency were washed with PBS and cultured in RPMI 1640 media containing 10% exosome-free FBS (System Biosciences, Palo Alto, CA, USA) under normoxia (21% O2) and hypoxia (1% O2) for 48 hrs. The conditioned media was collected and centrifuged for 10 min at 300 × g, 20 min at 2000 × g to remove cell debris, and 30 min at 10,000 × g to remove microvessicles larger than 200 nm. Subsequently, raw exosomes were collected by ultracentrifugation at 100,000 × g for 90 min in a SW 28 rotor (Beckman Coulter, Chaska, MN, USA). Exosome pellets were washed with PBS and passed through a 0.2 μm SFCA filter (Thermo Fisher Scientific, Waltham, MA, USA) to remove large contaminating lipid and vesicular aggregates. This preparation was ultracentrifuged at 100,000 × g for 90 min in a 70.1 Ti rotor (Beckman Coulter, Chaska, MN, USA). Exosomes derived from cells transfected with HIF-1α siRNAs and NTCs were isolated using the Exoquick reagent (System Biosciences, Palo Alto, CA, USA) with modifications to the vendor instructions. Briefly, conditioned media was centrifuged for 20 min at 2000 × g and 30 min at 10,000 × g. Next, Exoquick was added to the conditioned media and the remaining exosome precipitation steps were followed according to the manufacturer’s instructions. The exosome pellet was resuspended in 200 μl PBS and used immediately for co-culture assays or stored at –80°C.

Nanoparticle tracking analysis (NTA)

Exosomes were analyzed using a NanoSight NS300 (NanoSight Ltd, Navato, CA, USA). A red laser beam was used to visualize particles and assess their movement under Brownian motion. Illuminated particles were recorded and analyzed using the NTA software (NTA 3.1 Build 3.1.54) which applies the two-dimensional Stokes-Einstein equation to calculate size distribution and concentration of nano-sized particles.

Electron microscopy

Transmission electron microscopy (TEM) imaging of exosomes was performed as previously described [42], with some modifications. Briefly, exosomes were fixed for 1 hr in a mixture of 2% paraformaldehyde, 2% glutaraldehyde in 0.1 M Sorensen’s phosphate buffer. Following fixation, the exosome sample was layered on a formvar/silicon monoxide–coated 200 mesh grid and air-dried for 2 min. Grids were then stained with Nanovan negative stain (Nanoprobes, Yaphank, NY, USA) and air-dried for an additional 2 min. Samples were observed at 80Kv with a Tecnai G2 Transmission Electron Microscope (FEI Company, Hillsboro, OR, USA).

Sarcosphere assay

A673 and SK-ES-1 parental cells and cells transfected with CASP8AP2 siRNAs, NTCs, miR-210 mimics, miR-210 inhibitors and negative control mimics were cultured in serum-free media in non-adherent conditions. To prevent cell aggregations resulting in false positives, cells were seeded at low densities (20 cells/μL) in 6-well or 24-well Corning ultra-low attachment plates in sphere media composed of DMEM/F12 supplemented with 20 ng/mL EGF, 40 ng/mL bFGF, 2 μg/mL Heparin, 0.1 mM β-mercaptoethanol, 1% B27, 1% N2 and 1% penicillin/streptomycin. Sphere formation was assessed, microscopically, in cells grown under normoxia (21% O2) and hypoxia (1% O2) after 5 days. To assess sphere formation in EWS cells pre-treated with exosomes, EWS cells (1000 cells/well) were cultured at a low density (1 cell/μL) in 24-well low attachment plates with serum-free sphere media (as previously mentioned). Exosomes (20 μg/mL) derived from EWS cells cultured under normoxic and hypoxic conditions were added to A673 and SK-ES-1 cells, respectively. Sarcospheres were counted using a microscope after 5 days. All experiments were performed in triplicate.

For siRNA experiments, exosomes derived from EWS cells transfected with siHIF-1α or NTC were cultured with parental EWS cells and assessed for sphere formation after 5 days.

For miRNA experiments, EWS cells transfected with miR-210 inhibitors were co-cultured with hypoxic exosomes derived from their parental cell line as previously mentioned. Sphere formation and immunoblotting was assessed after 5 days.

Western blot

EWS cells (2 × 104 cells/well) were seeded in a 6-well ultra-low adherent plate (Corning) and pretreated with exosomes (0 or 20 μg/mL) in a sphere assay. Following 5 days, cells were harvested and lysed for use in western blot. Total protein was isolated from cells and exosomes using RIPA lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA). Protein from cells was quantified using the BCA method (Pierce, Waltham, MA, USA) and the amount of protein in exosomes was estimated by measuring protein content with the Bradford assay (Bio-Rad, Hercules, CA, USA). SDS-PAGE was conducted under reducing or non-reducing conditions followed by immunoblot as previously described [43]. Antibodies used in this experiment were TSG101, CD63, Calnexin (1:500, all Santa Cruz Biotechnology, Dallas, TX, USA), HIF-1α (1:1000, BD Biosciences, San Jose, CA, USA), CASP8AP2/FLASH (1:1000, Abcam, Cambrige, UK) and α-Tubulin (1:4000, Sigma Aldrich, St. Louis, MO, USA). Blots were incubated with appropriate horseradish peroxidase-tagged secondary antibodies and visualized using the MYECL Imager (Thermo Fisher Scientific, Waltham, MA, USA).

RNA isolation, RNA-seq and analysis

EWS cell and exosome total RNA was isolated using miRCURY™ RNA Isolation Kit according to the manufacturer’s protocol. RNA concentrations and quality were determined by ND-1000 (Nanodrop Technologies, Wimington, DE, USA) and Fragment Analyzer automated CE systems (Agilent, Santa Clara, CA, USA). Eletropherograms were generated using the Fragment Analyzer. Library preparation miRNA-seq used QIAseq miRNA Library Kit (Qiagen, Hilden, Germany), respectively. Sequencing was performed using the Illumina HiSeq3000 system (Illumina, San Diego, CA, USA). The miRNA count was calculated using the QIAseqmiRNA platform. The cutoff of differential miRNA was a fold-change threshold of 1.5 and maximum p-value of 0.05.

Real-time quantitative PCR

For miRNA quantification, miRNA was reverse transcribed and amplified using a Taqman MicroRNA assay kit (Applied Biosystems, Waltham, MA, USA). The Taqman probe based primers included has-miR-10b, has-miR-210 and endogenous controls RNU6B and has-miR-16 (Applied Biosystems, Waltham, MA, USA). miRNA RT-qPCR amplification was performed using the QuantSudio 3 instrument (Applied Biosystems, Waltham, MA, USA). Relative quantification was calculated using a comparartive Ct method.

Apoptosis assay

To detect apoptosis in EWS spheres transfected with NTC or siCASP8AP2, spheres were dissociated and fluorescently stained using an Annexin-V-FITC/PI flow cytometry assay kit (BD Biosciences, San Jose, CA) according to the manufacturer’s instructions. Quantification of apoptotic cells were performed using the FACSCalibur system (BD Biosciences, San Jose, CA).

Statistical analysis

Statistical analysis between groups were calculated using Student t test or one-way ANOVA with Tukey’s multiple comparisons test. A value of p ≤ 0.05 was considered statistically significant. All data is presented as mean ± standard error of the mean (SEM). ΔΔCq method was used to calculate relative gene expression from qRT-PCR data. All experiments were replicated a minimum of three times unless otherwise indicated.

ACKNOWLEDGMENTS

The authors thank the State of Nebraska for their financial support of the UNMC/Children’s Hospital Pediatric Cancer Research Program. The authors thank the Technology Center for Genomics and Bioinformatics Core Cacility at UCLA, TACGenomics and the Flow Cytometry, Electron Microscopy and Nanomaterials Characterization Core Facilities at UNMC for their assistance with these studies. The authors thank the Child Health Research Institute and the Fred Pamela Buffet Cancer Center supported Core Facilities at UNMC.

Author contributions

MJK, NKC, SSJ and JGS conceived and designed the study. MJK performed the experiments and wrote the manuscript. All authors assisted in analyzing and interpreting the data. All authors have read, participated in revising the manuscript and approved the final version of the manuscript.

CONFLICTS OF INTEREST

Authors have no conflicts of interest to declare.

FUNDING

This research was supported by the Pediatric Cancer Research Funds from the State of Nebraska (LB905; awarded to D.W. Coulter), UNMC Graduate Studies Assistantship/Fellowship and a University of Nebraska Presidential Graduate Fellowship awards.

REFERENCES

  • 1. Fraumeni JF Jr, Glass AG. Rarity of Ewing's sarcoma among U.S. Negro children. Lancet. 1970; 1:366–7. 10.1016/s0140-6736(70)90754-3. [DOI] [PubMed] [Google Scholar]
  • 2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992; 359:162–5. 10.1038/359162a0. [DOI] [PubMed] [Google Scholar]
  • 3. Riggi N, Stamenkovic I. The Biology of Ewing sarcoma. Cancer Lett. 2007; 254:1–10. 10.1016/j.canlet.2006.12.009. [DOI] [PubMed] [Google Scholar]
  • 4. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, Craft AW. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000; 18:3108–14. 10.1200/JCO.2000.18.17.3108. [DOI] [PubMed] [Google Scholar]
  • 5. Cornaz-Buros S, Riggi N, DeVito C, Sarre A, Letovanec I, Provero P, Stamenkovic I. Targeting cancer stem-like cells as an approach to defeating cellular heterogeneity in Ewing sarcoma. Cancer Res. 2014; 74:6610–22. 10.1158/0008-5472.CAN-14-1106. [DOI] [PubMed] [Google Scholar]
  • 6. Rankin EB, Nam JM, Giaccia AJ. Hypoxia: Signaling the Metastatic Cascade. Trends Cancer. 2016; 2:295–304. 10.1016/j.trecan.2016.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Bae KM, Dai Y, Vieweg J, Siemann DW. Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation. Am J Cancer Res. 2016; 6:1078–88. [PMC free article] [PubMed] [Google Scholar]
  • 8. Soni S, Padwad YS. HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta Oncol. 2017; 56:503–15. 10.1080/0284186X.2017.1301680. [DOI] [PubMed] [Google Scholar]
  • 9. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009; 15:501–13. 10.1016/j.ccr.2009.03.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Ludwig N, Yerneni SS, Razzo BM, Whiteside TL. Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells. Mol Cancer Res. 2018; 16:1798–808. 10.1158/1541-7786.MCR-18-0358. [DOI] [PubMed] [Google Scholar]
  • 11. Li L, Li C, Wang S, Wang Z, Jiang J, Wang W, Li X, Chen J, Liu K, Li C, Zhu G. Exosomes Derived from Hypoxic Oral Squamous Cell Carcinoma Cells Deliver miR-21 to Normoxic Cells to Elicit a Prometastatic Phenotype. Cancer Res. 2016; 76:1770–80. 10.1158/0008-5472.CAN-15-1625. [DOI] [PubMed] [Google Scholar]
  • 12. Ramteke A, Ting H, Agarwal C, Mateen S, Somasagara R, Hussain A, Graner M, Frederick B, Agarwal R, Deep G. Exosomes secreted under hypoxia enhance invasiveness and stemness of prostate cancer cells by targeting adherens junction molecules. Mol Carcinog. 2015; 54:554–65. 10.1002/mc.22124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Kalluri R. The biology and function of exosomes in cancer. J Clin Invest. 2016; 126:1208–15. 10.1172/JCI81135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Miller IV, Raposo G, Welsch U, Prazeres da Costa O, Thiel U, Lebar M, Maurer M, Bender HU, von Luettichau I, Richter GH, Burdach S, Grunewald TG. First identification of Ewing's sarcoma-derived extracellular vesicles and exploration of their biological and potential diagnostic implications. Biol Cell. 2013; 105:289–303. 10.1111/boc.201200086. [DOI] [PubMed] [Google Scholar]
  • 15. Ventura S, Aryee DN, Felicetti F, De Feo A, Mancarella C, Manara MC, Picci P, Colombo MP, Kovar H, Care A, Scotlandi K. CD99 regulates neural differentiation of Ewing sarcoma cells through miR-34a-Notch-mediated control of NF-kappaB signaling. Oncogene. 2016; 35:3944–54. 10.1038/onc.2015.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Villasante A, Marturano-Kruik A, Ambati SR, Liu Z, Godier-Furnemont A, Parsa H, Lee BW, Moore MA, Vunjak-Novakovic G. Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. Theranostics. 2016; 6:1119–30. 10.7150/thno.13944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Jung KO, Youn H, Lee CH, Kang KW, Chung JK. Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 2017; 8:9899–910. 10.18632/oncotarget.14247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Chan YC, Banerjee J, Choi SY, Sen CK. miR-210: the master hypoxamir. Microcirculation. 2012; 19:215–23. 10.1111/j.1549-8719.2011.00154.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Crescitelli R, Lasser C, Szabo TG, Kittel A, Eldh M, Dianzani I, Buzas EI, Lotvall J. Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles. 2013; 2. 10.3402/jev.v2i0.20677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Kim HW, Haider HK, Jiang S, Ashraf M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem. 2009; 284:33161–8. 10.1074/jbc.M109.020925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Wang F, Xiong L, Huang X, Zhao T, Wu LY, Liu ZH, Ding X, Liu S, Wu Y, Zhao Y, Wu K, Zhu LL, Fan M. miR-210 suppresses BNIP3 to protect against the apoptosis of neural progenitor cells. Stem Cell Res. 2013; 11:657–67. 10.1016/j.scr.2013.04.005. [DOI] [PubMed] [Google Scholar]
  • 22. Wang B, Gu TX, Yu FM, Zhang GW, Zhao Y. Overexpression of miR-210 promotes the potential of cardiac stem cells against hypoxia. Scand Cardiovasc J. 2018; 52:367–71. 10.1080/14017431.2019.1567932. [DOI] [PubMed] [Google Scholar]
  • 23. Kim HW, Mallick F, Durrani S, Ashraf M, Jiang S, Haider KH. Concomitant activation of miR-107/PDCD10 and hypoxamir-210/Casp8ap2 and their role in cytoprotection during ischemic preconditioning of stem cells. Antioxid Redox Signal. 2012; 17:1053–65. 10.1089/ars.2012.4518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Dunst J, Stadler P, Becker A, Kuhnt T, Lautenschlager C, Molls M, Haensgen G. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol. 2001; 177:469–73. 10.1007/pl00002428. [DOI] [PubMed] [Google Scholar]
  • 25. Baroni S, Romero-Cordoba S, Plantamura I, Dugo M, D'Ippolito E, Cataldo A, Cosentino G, Angeloni V, Rossini A, Daidone MG, Iorio MV. Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis. 2016; 7:e2312. 10.1038/cddis.2016.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Zhou X, Yan T, Huang C, Xu Z, Wang L, Jiang E, Wang H, Chen Y, Liu K, Shao Z, Shang Z. Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway. J Exp Clin Cancer Res. 2018; 37:242. 10.1186/s13046-018-0911-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer. 2012; 12:421. 10.1186/1471-2407-12-421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Reclusa P, Taverna S, Pucci M, Durendez E, Calabuig S, Manca P, Serrano MJ, Sober L, Pauwels P, Russo A, Rolfo C. Exosomes as diagnostic and predictive biomarkers in lung cancer. J Thorac Dis. 2017; 9:S1373–S82. 10.21037/jtd.2017.10.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Singh R, Pochampally R, Watabe K, Lu Z, Mo YY. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer. 2014; 13:256. 10.1186/1476-4598-13-256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, Song J, Li Z, Zhang Z, Yuan W. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018; 17:147. 10.1186/s12943-018-0897-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell. 2014; 26:707–21. 10.1016/j.ccell.2014.09.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Figueroa J, Phillips LM, Shahar T, Hossain A, Gumin J, Kim H, Bean AJ, Calin GA, Fueyo J, Walters ET, Kalluri R, Verhaak RG, Lang FF. Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. Cancer Res. 2017; 77:5808–19. 10.1158/0008-5472.CAN-16-2524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Yang W, Wei J, Guo T, Shen Y, Liu F. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance. Exp Cell Res. 2014; 326:22–35. 10.1016/j.yexcr.2014.05.022. [DOI] [PubMed] [Google Scholar]
  • 34. Zhang H, Mai Q, Chen J. MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line. Cell Biol Int. 2017; 41:267–75. 10.1002/cbin.10721. [DOI] [PubMed] [Google Scholar]
  • 35. Imai Y, Kimura T, Murakami A, Yajima N, Sakamaki K, Yonehara S. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis. Nature. 1999; 398:777–85. 10.1038/19709. [DOI] [PubMed] [Google Scholar]
  • 36. Li T, Song X, Zhang J, Zhao L, Shi Y, Li Z, Liu J, Liu N, Yan Y, Xiao Y, Tian X, Sun W, Guan Y, et al. Protection of Human Umbilical Vein Endothelial Cells against Oxidative Stress by MicroRNA-210. Oxid Med Cell Longev. 2017; 2017:3565613. 10.1155/2017/3565613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt- and p53-dependent pathways and exerts cytoprotective effects. Am J Physiol Heart Circ Physiol. 2011; 301:H1519–30. 10.1152/ajpheart.01080.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Liu C, Tang X. Downregulation of microRNA-210 inhibits osteosarcoma growth in vitro and in vivo . Mol Med Rep. 2015; 12:3674–80. 10.3892/mmr.2015.3880. [DOI] [PubMed] [Google Scholar]
  • 39. Kilic-Eren M, Boylu T, Tabor V. Targeting PI3K/Akt represses Hypoxia inducible factor-1alpha activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosis. Cancer Cell Int. 2013; 13:36. 10.1186/1475-2867-13-36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene. 2007; 26:2027–38. 10.1038/sj.onc.1210008. [DOI] [PubMed] [Google Scholar]
  • 41. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; Chapter 3:Unit 3.22. 10.1002/0471143030.cb0322s30. [DOI] [PubMed] [Google Scholar]
  • 42. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996; 183:1161–72. 10.1084/jem.183.3.1161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Chaturvedi NK, McGuire TR, Coulter DW, Shukla A, McIntyre EM, Sharp JG, Joshi SS. Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan. Oncotarget. 2016; 7:15215–29. 10.18632/oncotarget.7714. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES